SCHEMBL901696

SCHEMBL901696

CCOC(=O)CCc1ccc(Cl)cc1Cl

nearest known ligand 0.57

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CYP4F2 P78329 2/20 0.53
CYP4A11 Q02928 2/20 0.53
CYP3A4 P08684 1/20 0.48
CYP2C9 P11712 1/20 0.48
PDPK1 O15530 1/20 0.48
LMNA P02545 2/20 0.47
SMN1; SMN2 Q16637 1/20 0.47
TDP1 Q9NUW8 1/20 0.46
MEN1 O00255 1/20 0.46
HPGD P15428 1/20 0.46
KMT2A Q03164 1/20 0.46
NPC1 O15118 1/20 0.45
POLB P06746 1/20 0.45
TSHR P16473 1/20 0.45
RAB9A P51151 1/20 0.45
ALOX15 P16050 1/20 0.45
GAA P10253 2/20 0.45
KDM4E B2RXH2 2/20 0.45
ADCY8 P40145 1/20 0.44
ALDH1A1 P00352 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL8361251 0.88 CYP4F2 (0.53) CYP4F2CYP4A11CYP3A4CYP2C9SMN1; SMN2
SCHEMBL5990825 0.86 CYP4F2 (0.51) CYP4F2CYP4A11HPGDKMT2AGAA
SCHEMBL27176866 0.85 CYP4F2 (0.66) CYP4F2CYP4A11CYP3A4CYP2C9LMNA
SCHEMBL22124308 0.85 CYP4F2 (0.50) CYP4F2CYP4A11CYP3A4CYP2C9LMNA
SCHEMBL8361248 0.85 CYP4F2 (0.50) CYP4F2CYP4A11CYP3A4CYP2C9LMNA
SCHEMBL31441299 0.84 KMT2A (0.57) CYP3A4CYP2C9LMNASMN1; SMN2TDP1
SCHEMBL707398 0.84 KMT2A (0.57) CYP3A4CYP2C9LMNASMN1; SMN2TDP1
SCHEMBL11532393 0.84 MAPT (0.57) CYP3A4PDPK1HPGDPOLBGAA
SCHEMBL27176902 0.84 CYP4F2 (0.49) CYP4F2CYP4A11CYP3A4CYP2C9LMNA
SCHEMBL28366037 0.84 CYP4F2 (0.49) CYP4F2CYP4A11LMNAMEN1HPGD

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20130252951-A1 7-HYDROXY-PYRAZOLO[1,5-A] PYRIMIDINE COMPOUNDS AND THEIR USE AS CCR2 RECEPTOR ANTAGONISTS PROXIMAGEN LIMITED (GB) 2013-09-26 US disclosed
EP-2621928-A1 7-HYDROXY-PYRAZOLO[1,5-A]PYRIMIDINE COMPOUNDS AND THEIR USE AS CCR2 RECEPTOR ANTAGONISTS Proximagen Limited (GB) 2013-08-07 EP disclosed
WO-2012041817-A1 7-HYDROXY-PYRAZOLO[1,5-A] PYRIMIDINE COMPOUNDS AND THEIR USE AS CCR2 RECEPTOR ANTAGONISTS PROXIMAGEN LTD (GB) 2012-04-05 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20130252951-A1 7-HYDROXY-PYRAZOLO[1,5-A] PYRIMIDINE COMPOUNDS AND THEIR USE AS CCR2 RECEPTOR ANTAGONISTS CCR2, CCR5, CCR1 CYP4F2 1184/4885CYP4A11 639/4885CYP3A4 536/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.